Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

A Prospective, Randomized Study of Cyclosporine or Corticosteroids As an Adjunct to Plasma Exchange for the Treatment of Thrombotic Thrombocytopenic Purpura

Spero Cataland, Shangbin Yang, PhD, Camila Masias Castanon, MD, Michael McGookey, Haiwa Wu, Susan Geyer, PhD, James N. George, MD, Lauren Jay, Haifeng M Wu, MD

Blood (2016) 128 (22): 133.

https://doi.org/10.1182/blood.V128.22.133.133

Published: 2016

Journal Articles

Headache Prevalence Following Recovery from TTP and aHUS: A Single-Center, Cross Sectional Cohort Survey Study

Jennifer N Saultz, DO, Haifeng M Wu, MD, Spero R Cataland, MD

Blood (2014) 124 (21): 4826.

https://doi.org/10.1182/blood.V124.21.4826.4826

Published: 2014

Journal Articles

Time-Dependent Activation of Complement system during Storage of Platelet Product

Jian Chen, MD PhD, Shangbin Yang, PhD, Spero R Cataland, MD, Haifeng M Wu, MD

Blood (2014) 124 (21): 4287.

https://doi.org/10.1182/blood.V124.21.4287.4287

Published: 2014

Journal Articles

Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP

Spero R. Cataland, V. Michael Holers, Susan Geyer, Shangbin Yang, Haifeng M. Wu

Blood (2014) 123 (24): 3733–3738.

https://doi.org/10.1182/blood-2013-12-547067

Published: 2014

Includes: Supplemental data

Journal Articles

How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome

Spero R. Cataland, Haifeng M. Wu

Blood (2014) 123 (16): 2478–2484.

https://doi.org/10.1182/blood-2013-11-516237

Published: 2014

Journal Articles

Alternative and Terminal Complement Pathway Biomarkers At Presentation More Precisely Define The Clinical Diagnosis Of aHUS

Spero R Cataland, M.D., V. Michael Holers, M.D., Shangbin Yang, Ph.D., Haifeng M Wu, M.D.

Blood (2013) 122 (21): 3552.

https://doi.org/10.1182/blood.V122.21.3552.3552

Published: 2013

Journal Articles

Diagnostic and Prognostic Values Of ADAMTS13 Activity Measured During Daily Plasma Exchange Therapy In Patients With Acquired TTP

Nan Wu, Shangbin Yang, Ph.D., Spero R Cataland, M.D., Haifeng M Wu, M.D.

Blood (2013) 122 (21): 1079.

https://doi.org/10.1182/blood.V122.21.1079.1079

Published: 2013

Journal Articles

Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura

Luca A. Lotta, Haifeng M. Wu, Ian J. Mackie, Marina Noris, Agnes Veyradier, Marie A. Scully, Giuseppe Remuzzi, Paul Coppo, Ri Liesner, Roberta Donadelli, Chantal Loirat, Richard A. Gibbs, April Horne, Shangbin Yang, Isabella Garagiola, Khaled M. Musallam, Flora Peyvandi

Blood (2012) 120 (2): 440–448.

https://doi.org/10.1182/blood-2012-01-403113

Published: 2012

Includes: Supplemental data

Journal Articles

Residual Plasmatic Activity of ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura Correlates with Disease Phenotype

Luca A Lotta, Haifeng M Wu, Marie A Scully, Marina Noris, Agnes Veyradier, Ian J Mackie, PhD FRCPath, Giuseppe Remuzzi, Paul Coppo, Ri Liesner, Roberta Donadelli, Chantal Loirat, MD, Richard A Gibbs, April Horne, Shangbin Yang, Roberta Palla, Flora Peyvandi

Blood (2011) 118 (21): 2219.

https://doi.org/10.1182/blood.V118.21.2219.2219

Published: 2011

Journal Articles

ADAMTS13 Antigen Levels and the Risk of Relapse during Long-Term Clinical Follow Up of Patients with Idiopathic Thrombotic Thrombocytopenic Purpura.

Spero R. Cataland, MD, Ming Jin, PhD, Shili Lin, PhD, Melanie Kennedy, MD, Eric H. Kraut, MD, James N. George, MD, Haifeng M. Wu, MD

Blood (2007) 110 (11): 3204.

https://doi.org/10.1182/blood.V110.11.3204.3204

Published: 2007

Journal Articles

Low ADAMTS13 Activity in Clinical Remission Predicts the Risk of TTP Relapses.

Haifeng M. Wu, MD, T. Charles Casper, Spero R. Cataland, M.D., Shili Lin, Ph.D., Melanie Kennedy, M.D., Ming Jin, Ph.D.

Blood (2007) 110 (11): 4018.

https://doi.org/10.1182/blood.V110.11.4018.4018

Published: 2007

Journal Articles

Improved Clinical Outcome and ADAMTS13 Activity after Concurrent Cyclosporine and Plasma Exchange in TTP.

Spero R. Cataland, MD, Eric H. Kraut, MD, Don Benson, MD, PhD, Amy K. Ferketich, PhD, April Horne, Ming Jin, PhD, James N. George, MD, Haifeng M. Wu, MD

Blood (2006) 108 (11): 1056.

https://doi.org/10.1182/blood.V108.11.1056.1056

Published: 2006

Journal Articles

Cyclosporine and Plasma Exchange Is Superior to Corticosteroids and Plasma Exchange as Initial Therapy of TTP.

Spero R. Cataland, MD, Ming Jin, PhD, Amy K. Ferketich, PhD, Eric H. Kraut, MD, James N. George, MD, Haifeng M. Wu, MD

Blood (2005) 106 (11): 1235.

https://doi.org/10.1182/blood.V106.11.1235.1235

Published: 2005

Journal Articles

Cyclosporine Alone for the Treatment of Early Recurrences of TTP.

Spero R. Cataland, MD, Ming Jin, PhD, Amy K. Ferketich, PhD, X. Long Zheng, MD, PhD, James N. George, MD, Haifeng M. Wu, MD

Blood (2005) 106 (11): 1236.

https://doi.org/10.1182/blood.V106.11.1236.1236

Published: 2005

Journal Articles

Distinguishing Antiphospholipid Antibodies from an Acquired Factor Inhibitor: A Novel Laboratory Approach.

Kurt P. Leuenberger, MD, Spero Cataland, MD, Ming Jin, MD, PhD, Carol Orr, Guido Marcucci, MD, Eric H. Kraut, MD, Haifeng M. Wu, MD

Blood (2005) 106 (11): 2150.

https://doi.org/10.1182/blood.V106.11.2150.2150

Published: 2005

Journal Articles

Improved Clinical Outcome and ADAMTS13 Activity Following Cyclosporine Therapy in Patients with TTP.

Spero R. Cataland, M.D., James N. George, M.D., Eric H. Kraut, M.D., Tran T. Bourgeois, Amy K. Ferketich, Ph.D., Melanie S. Kennedy, M.D., Michael A. Caligiuri, M.D., Haifeng M. Wu, M.D., Ph.D.

Blood (2004) 104 (11): 851.

https://doi.org/10.1182/blood.V104.11.851.851

Published: 2004

NARROW

A Prospective, Randomized Study of Cyclosporine or Corticosteroids As an Adjunct to Plasma Exchange for the Treatment of Thrombotic Thrombocytopenic Purpura

Headache Prevalence Following Recovery from TTP and aHUS: A Single-Center, Cross Sectional Cohort Survey Study

Time-Dependent Activation of Complement system during Storage of Platelet Product

Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP

How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome

Alternative and Terminal Complement Pathway Biomarkers At Presentation More Precisely Define The Clinical Diagnosis Of aHUS

Diagnostic and Prognostic Values Of ADAMTS13 Activity Measured During Daily Plasma Exchange Therapy In Patients With Acquired TTP

Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura

Residual Plasmatic Activity of ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura Correlates with Disease Phenotype

ADAMTS13 Antigen Levels and the Risk of Relapse during Long-Term Clinical Follow Up of Patients with Idiopathic Thrombotic Thrombocytopenic Purpura.

Low ADAMTS13 Activity in Clinical Remission Predicts the Risk of TTP Relapses.

Improved Clinical Outcome and ADAMTS13 Activity after Concurrent Cyclosporine and Plasma Exchange in TTP.

Cyclosporine and Plasma Exchange Is Superior to Corticosteroids and Plasma Exchange as Initial Therapy of TTP.

Cyclosporine Alone for the Treatment of Early Recurrences of TTP.

Distinguishing Antiphospholipid Antibodies from an Acquired Factor Inhibitor: A Novel Laboratory Approach.

Improved Clinical Outcome and ADAMTS13 Activity Following Cyclosporine Therapy in Patients with TTP.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only